Cyclacel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Bio Green Med Solution

19/03/2024 21:01

* Cyclacel Pharmaceuticals Inc  CYCC.OQ  reported a
quarterly
adjusted loss of $6.23​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-9.00.  The mean expectation of
three analysts for the quarter was for a loss of $5.89 per
share. Wall Street expected results to range from $-7.07
to $-4.98 per share.
    * Revenue was $31.00 thousand​; analysts expected zero. 
    * Cyclacel Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $6.23​.
    * The company reported a quarterly loss of $5.32 million.
    * Cyclacel Pharmaceuticals Inc shares had fallen by 6.0%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 16.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cyclacel
Pharmaceuticals Inc is $93.00 
This summary was machine generated from LSEG data March 19 at
09:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -5.89          -6.23          Missed
 Sep. 30 2023      -5.45          -7.35          Missed
 Jun. 30 2023      -7.55          -6.60          Beat
 Mar. 31 2023      -9.95          -7.05          Beat